English | Español

Eli Lilly And Company
Patient Daily | May 25, 2023

Lilly ESG Report Highlights Progress Towards Sustainability Goals
Patient Daily | May 24, 2023

Lilly's peresolimab Phase 2a rheumatoid arthritis trial published in The New England Journal of Medicine
Patient Daily | May 22, 2023

Loxo@Lilly Announces Details of Presentations at 2023 European Hematology Association (EHA) Annual Meeting
Patient Daily | May 9, 2023

Lilly Provides $500,000 in Grants to Support Equitable Access to Education for Dreamers in Indiana
Patient Daily | May 9, 2023

Lilly Declares Second-Quarter 2023 Dividend
Patient Daily | May 9, 2023

Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2
Patient Daily | Apr 26, 2023

Lilly to Divest BAQSIMI to Amphastar
Patient Daily | Apr 26, 2023

Lilly to Make Record-Breaking Investment in Indiana Manufacturing Facilities

Trending
+ Technology/Innovation
Patient Daily | May 8, 2025

Medfluence attends 2025 Annual Clinical Assembly as only strategic marketing firm
+ Technology/Innovation
Patient Daily | May 7, 2025

OTO Forum 2025 highlights innovation in ENT
+ Pharmaceuticals
Patient Daily | May 8, 2025

Pacific Research Institute CEO: Hospitals are leveraging 340B's 'perverse incentives to enrich themselves'
+ Pharmaceuticals
Patient Daily | May 8, 2025

National Library of Medicine says compounded drugs like GLP-1 offer tailored alternatives to FDA-approved treatments